Prosecution Insights
Prosecution Insights
Technology area: Biotechnology & Pharmaceuticals
1 pending office actions • 1 art units • 1 examiners • 0 of 1 (0%) have an AI response strategy ready • 2 patents granted in the last 365 days
Intrabio Limited currently manages 1 pending office action within the Biotechnology & Pharmaceuticals technology area. This 1 pending office action is assigned to 1 distinct examiner, which indicates a concentrated prosecution strategy. The 1 distinct examiner, JAVANMARD, SAHAR, is responsible for the 1 busiest examiner pending action currently on the docket.
The portfolio is active within 1 distinct art unit, meaning the technical evaluation is confined to a single specialized group. This 1 distinct art unit provides a consistent environment for the company's biotechnology and pharmaceutical filings. JAVANMARD, SAHAR is identified as the busiest examiner, overseeing the active matters for the company.
For practitioners, the presence of 1 busiest examiner pending action suggests that progress is tied to the specific tendencies of a single individual. The Biotechnology & Pharmaceuticals technology area classification remains the focus for this 1 pending office action. This structure ensures a streamlined approach without the involvement of other examiners.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §103 only | 1 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| JAVANMARD, SAHAR | 1 | 64.8% | +34.1% |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18411512 | THERAPEUTIC AGENTS FOR NEURODEGENERATIVE DISEASES | JAVANMARD, SAHAR | — |
| Art Unit | Apps |
|---|---|
| 1622 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18411512 | THERAPEUTIC AGENTS FOR NEURODEGENERATIVE DISEASES | JAVANMARD, SAHAR | 1622 | §103Other | Non-Final OA | — | Pending | Jan 12, 2024 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial